Banque Cantonale Vaudoise Raises Position in Biogen Inc. $BIIB

Banque Cantonale Vaudoise increased its stake in Biogen Inc. (NASDAQ:BIIB) by 129.0% during the 1st quarter, Holdings Channel reports. The fund owned 7,928 shares of the biotechnology company’s stock after purchasing an additional 4,466 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Biogen were worth $1,453,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Reflection Asset Management purchased a new stake in Biogen during the 4th quarter worth about $25,000. WPG Advisers LLC raised its position in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares in the last quarter. First Horizon Corp purchased a new position in shares of Biogen in the 4th quarter valued at about $30,000. Root Financial Partners LLC grew its position in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after buying an additional 123 shares in the last quarter. Finally, MV Capital Management Inc. purchased a new stake in shares of Biogen during the fourth quarter worth approximately $34,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $216.03 on Friday. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $218.06. The company has a 50-day moving average price of $193.37 and a 200 day moving average price of $185.67. The company has a market cap of $31.89 billion, a P/E ratio of 23.18 and a beta of 0.20. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Research analysts predict that Biogen Inc. will post 13.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BIIB has been the topic of several analyst reports. Wedbush raised their target price on shares of Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a report on Thursday, April 30th. Morgan Stanley increased their price objective on shares of Biogen from $206.00 to $224.00 and gave the company an “equal weight” rating in a research report on Thursday, June 18th. Citigroup raised their price objective on shares of Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Argus raised shares of Biogen to a “hold” rating in a research report on Thursday, April 9th. Finally, Piper Sandler reiterated an “overweight” rating and set a $225.00 target price (up from $214.00) on shares of Biogen in a research note on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $217.37.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.